CASR and neuroendocrine neoplasm: This indicates that targeting CaSR expression could be beneficial in reducing proliferation in neuroendocrine tumours, such as corticotrophinomas that represent up to 10% of all surgically removed pituitary adenomas (Daly et al. 2009), however, this remains to be tested in detail.